Platinol-AQ clinical trials
Platinol-AQ is named as an intervention in 50 current clinical trials in our Mexico, Canada, Israel, Australia, Japan, Poland, USA, China, France, Spain, Taiwan, UK, Germany, South Korea, Italy, Turkey, Norway, Ireland, Belgium, Brazil, Netherlands, Austria, Sweden, Singapore, Switzerland, Portugal, Czechia, Denmark, Egypt and India registers. 21 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (22). The most-studied condition is Stage III Lung Cancer AJCC v8.
Patient leaflets for Platinol-AQ
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Platinol-AQ
50 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Platinol-AQ
124 conditionsAll 124 conditions
| Condition (as registered) | Trials |
|---|---|
| Stage III Lung Cancer AJCC v8 | 4 |
| Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | 4 |
| Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | 3 |
| Endometrial Neoplasms | 2 |
| Metastatic Non-small Cell Lung Cancer | 2 |
| Stage II Lung Cancer AJCC v8 | 2 |
| Bladder Urothelial Carcinoma | 2 |
| Stage II Bladder Cancer AJCC v8 | 2 |
| Stage IIIA Bladder Cancer AJCC v8 | 2 |
| Stage IIB Lung Cancer AJCC v8 | 2 |
| Lung Non-Squamous Non-Small Cell Carcinoma | 2 |
| Stage IV Nasopharyngeal Carcinoma AJCC v8 | 2 |
| Ganglioneuroblastoma, Nodular | 2 |
| Neuroblastoma | 2 |
| Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | 2 |
| Head and Neck Squamous Cell Carcinoma | 2 |
| Recurrent Hypopharyngeal Squamous Cell Carcinoma | 2 |
| Recurrent Laryngeal Squamous Cell Carcinoma | 2 |
| Advanced Head and Neck Squamous Cell Carcinoma | 1 |
| Advanced Hypopharyngeal Squamous Cell Carcinoma | 1 |
| Advanced Laryngeal Squamous Cell Carcinoma | 1 |
| Advanced Oropharyngeal Squamous Cell Carcinoma | 1 |
| Small Cell Lung Carcinoma | 1 |
| Head and Neck Neoplasms | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Non-small Cell Lung Cancer | 1 |
| Bladder Cancer | 1 |
| Childhood Extracranial Germ Cell Tumor | 1 |
| Extragonadal Embryonal Carcinoma | 1 |
| Germ Cell Tumor | 1 |
| Malignant Germ Cell Tumor | 1 |
| EBV Infection | 1 |
| Stage II Nasopharyngeal Carcinoma AJCC v7 | 1 |
| Stage III Nasopharyngeal Carcinoma AJCC v7 | 1 |
| Stage IVA Nasopharyngeal Carcinoma AJCC v7 | 1 |
| ENSAT Stage I Adrenal Cortex Carcinoma | 1 |
| ENSAT Stage II Adrenal Cortex Carcinoma | 1 |
| ENSAT Stage III Adrenal Cortex Carcinoma | 1 |
| Limited Stage Lung Small Cell Carcinoma | 1 |
| Stage I Lung Cancer AJCC v8 | 1 |
| Muscle Invasive Bladder Carcinoma | 1 |
| Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | 1 |
| Stage II Lung Non-Small Cell Cancer AJCC v7 | 1 |
| Stage IIA Lung Cancer AJCC v8 | 1 |
| Lung Non-Small Cell Carcinoma | 1 |
| Lung Non-Small Cell Squamous Carcinoma | 1 |
| Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 |
| Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 |
| Stage I Bladder Cancer AJCC v8 | 1 |
| Stage II Nasopharyngeal Carcinoma AJCC v8 | 1 |
| Stage III Nasopharyngeal Carcinoma AJCC v8 | 1 |
| Locally Advanced Pancreatic Adenocarcinoma | 1 |
| Metastatic Pancreatic Adenocarcinoma | 1 |
| Stage III Pancreatic Cancer AJCC v8 | 1 |
| Stage IV Pancreatic Cancer AJCC v8 | 1 |
| Muscle Invasive Bladder Urothelial Carcinoma | 1 |
| Non Small Cell Lung Cancer | 1 |
| Complete Surgical Resection | 1 |
| Circulating Tumor DNA | 1 |
| Metastatic Nasopharyngeal Carcinoma | 1 |
| Recurrent Nasopharyngeal Carcinoma | 1 |
| Childhood Medulloblastoma | 1 |
| Childhood Hepatocellular Carcinoma | 1 |
| Childhood Malignant Liver Neoplasm | 1 |
| Fibrolamellar Carcinoma | 1 |
| Hepatoblastoma | 1 |
| Ganglioneuroblastoma | 1 |
| Advanced Bile Duct Carcinoma | 1 |
| Advanced Breast Carcinoma | 1 |
| Advanced Cervical Carcinoma | 1 |
| Advanced Endometrial Carcinoma | 1 |
| Advanced Vaginal Adenocarcinoma | 1 |
| Advanced Vaginal Adenosquamous Carcinoma | 1 |
| Advanced Vaginal Squamous Cell Carcinoma | 1 |
| Cervical Adenocarcinoma | 1 |
| Head and Neck Carcinoma of Unknown Primary | 1 |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | 1 |
| Medulloblastoma | 1 |
| Locally Advanced Lung Non-Small Cell Carcinoma | 1 |
| Basaloid Squamous Cell Carcinoma | 1 |
| Oropharyngeal Squamous Cell Carcinoma | 1 |
| Estrogen Receptor Negative | 1 |
| HER2/Neu Negative | 1 |
| Invasive Breast Carcinoma | 1 |
| Progesterone Receptor Negative | 1 |
| Renal Pelvis and Ureter Urothelial Carcinoma | 1 |
| Human Papilloma Virus Infection | 1 |
| Stage III Squamous Cell Carcinoma of the Oropharynx | 1 |
| Stage IVA Squamous Cell Carcinoma of the Oropharynx | 1 |
| Stage IVB Squamous Cell Carcinoma of the Oropharynx | 1 |
| Recurrent Lung Non-Small Cell Carcinoma | 1 |
| Stage IIIA Lung Cancer AJCC v8 | 1 |
| Stage IIIB Lung Cancer AJCC v8 | 1 |
| Locally Advanced Cervical Adenocarcinoma | 1 |
| Locally Advanced Cervical Adenosquamous Carcinoma | 1 |
| Locally Advanced Cervical Squamous Cell Carcinoma | 1 |
| Stage IIIA Cervical Cancer FIGO 2018 | 1 |
| Neck Squamous Cell Carcinoma of Unknown Primary | 1 |
| Recurrent Laryngeal Verrucous Carcinoma | 1 |
| Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | 1 |
| Metastatic Head and Neck Squamous Cell Carcinoma | 1 |
| Metastatic Hypopharyngeal Squamous Cell Carcinoma | 1 |
| Metastatic Laryngeal Squamous Cell Carcinoma | 1 |
| Recurrent Head and Neck Squamous Cell Carcinoma | 1 |
| Recurrent Oral Cavity Squamous Cell Carcinoma | 1 |
| Hypopharyngeal Squamous Cell Carcinoma | 1 |
| Laryngeal Squamous Cell Carcinoma | 1 |
| Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant | 1 |
| Stage II Gallbladder Cancer AJCC v8 | 1 |
| Stage IIA Gallbladder Cancer AJCC v8 | 1 |
| Stage IIB Gallbladder Cancer AJCC v8 | 1 |
| Stage III Gallbladder Cancer AJCC v8 | 1 |
| Stage III Bladder Cancer AJCC v8 | 1 |
| Gastric Neuroendocrine Carcinoma | 1 |
| Intestinal Neuroendocrine Carcinoma | 1 |
| Pancreatic Neuroendocrine Carcinoma | 1 |
| Vulvar Cancer | 1 |
| Vulvar Squamous Cell Carcinoma | 1 |
| Bile Duct Cancer | 1 |
| Cholangiocarcinoma | 1 |
| Cholangiocarcinoma Non-resectable | 1 |
| Cholangiocarcinoma Metastatic | 1 |
| Lung Adenocarcinoma | 1 |
| Lung Large Cell Carcinoma | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Platinol-AQ trials
How many clinical trials are testing Platinol-AQ?
50 current trials in our Mexico, Canada, Israel, Australia, Japan, Poland, USA, China, France, Spain, Taiwan, UK, Germany, South Korea, Italy, Turkey, Norway, Ireland, Belgium, Brazil, Netherlands, Austria, Sweden, Singapore, Switzerland, Portugal, Czechia, Denmark, Egypt and India registers name Platinol-AQ (also registered as Cisplatin /m^2) as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Platinol-AQ trials recruiting patients?
Yes. 21 of the 50 trials are recruiting: 11 with sites in Mexico, 13 with sites in Canada, 10 with sites in Israel, 6 with sites in Australia, 3 with sites in Japan, 3 with sites in Poland, 2 with sites in USA, 2 with sites in China, 3 with sites in France, 2 with sites in Spain, 2 with sites in Taiwan, 2 with sites in UK, 2 with sites in Germany, 2 with sites in South Korea, 2 with sites in Italy, 2 with sites in Turkey, 1 with sites in Norway, 1 with sites in Ireland, 2 with sites in Belgium, 2 with sites in Brazil, 2 with sites in Netherlands, 1 with sites in Austria, 2 with sites in Sweden, 2 with sites in Singapore, 1 with sites in Switzerland and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Platinol-AQ clinical trials?
National Cancer Institute (NCI) (22), Merck Sharp & Dohme LLC (9), NRG Oncology (5) and Children's Oncology Group (5), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Platinol-AQ clinical trials in Ireland?
Yes. 5 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Platinol-AQ works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Platinol-AQ works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Platinol-AQ (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.